# BMT CTN 0803

Source: https://onco.cc/trials/bmt-ctn-0803/  
OnCo record `bmt-ctn-0803` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BMT CTN 0803 showed that people living with HIV whose lymphoma had come back can have the same high-dose chemotherapy and stem cell transplant as anyone else, with 87 percent alive at one year and outcomes no different from matched HIV-negative patients, so HIV alone should not bar transplant.

## Summary

BMT CTN 0803/AMC 071 was a single-arm phase 2 trial of the Blood and Marrow Transplant Clinical Trials Network and the AIDS Malignancy Consortium in 43 HIV-infected patients with chemotherapy-sensitive relapsed or persistent aggressive B-cell or Hodgkin lymphoma; 40 underwent autologous transplant after BEAM conditioning with protocol-defined management of antiretroviral therapy around transplant. The primary endpoint was one-year overall survival.

At a median follow-up of 24.8 months, one- and two-year overall survival were 87.3 and 82 percent, two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent; engraftment was prompt and outcomes did not differ from 151 matched HIV-negative registry controls. The corpus's HIV-associated lymphoma page cites BMT CTN 0803 for autologous transplant being feasible with controlled HIV.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-22
- Also known as: BMTCTN0803; CTN 0803; AMC 071
- Tags: soc-trials
- Registry id: NCT01141712
- Phase: 2
- Setting: HIV-infected patients over 15 with chemotherapy-sensitive relapsed or persistent aggressive B-cell lymphoma or Hodgkin lymphoma and treatable HIV: high-dose carmustine, etoposide, cytarabine and melphalan (BEAM) with autologous stem cell transplant and consistent peri-transplant antiretroviral management
- Sponsor: Medical College of Wisconsin
- Enrolled: 43
- Result: One-year overall survival 87.3 percent and two-year overall survival 82 percent after autologous transplant, with two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent, no different from matched HIV-negative controls.
- Outcomes: Overall survival at 1 year: BEAM and autologous transplant in HIV-infected patients 87.3%; Overall survival at 2 years: BEAM and autologous transplant in HIV-infected patients 82%; Progression-free survival at 2 years: BEAM and autologous transplant in HIV-infected patients 79.8%; Transplant-related mortality at 1 year: BEAM and autologous transplant in HIV-infected patients 5.2%

## Sources

- ClinicalTrials.gov NCT01141712: https://clinicaltrials.gov/study/NCT01141712

## Connected records

- cancers: [HIV-associated (AIDS-related) lymphomas](https://onco.cc/cancers/hiv-associated-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- technologies: [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Carmustine](https://onco.cc/drugs/carmustine/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Etoposide](https://onco.cc/drugs/etoposide/), [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/)
- institutions: [Medical College of Wisconsin Cancer Center](https://onco.cc/institutions/mcw-cancer-center/)
- key papers: [BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma](https://onco.cc/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/)

---
JSON: https://onco.cc/api/v1/entities/bmt-ctn-0803.json